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Abstract
Background Autopsy of sudden cardiac death (SCD) in the
young shows a structurally and histologically normal heart in
about one third of cases. Sudden death in these cases is be-
lieved to be attributed in a high percentage to inherited ar-
rhythmogenic diseases. The purpose of this study was to in-
vestigate the value of performing post-mortem genetic analy-
sis for autopsy-negative sudden unexplained death (SUD) in 1
to 35 year olds.
Methods and results From January 2009 to December 2011,
samples from 15 cases suffering SUD were referred to the
Department of Clinical Genetics, Umeå University Hospital,
Sweden, for molecular genetic evaluation. PCR and bidirec-
tional Sanger sequencing of genes important for long QT syn-
drome (LQTS), short QT syndrome (SQTS), Brugada syn-
drome type 1 (BrS1), and catecholaminergic polymorphic
ventricular tachycardia (CPVT) (KCNQ1, KCNH2, SCN5A,
KCNE1, KCNE2, and RYR2) was performed. Multiplex
ligation-dependent probe amplification (MLPA) was used to
detect large deletions or duplications in the LQTS genes. Six
pathogenic sequence variants (four LQTS and two CPVT)
were discovered in 15 SUD cases (40 %). Ten first-degree
family members were found to be mutation carriers (seven
LQTS and three CPVT).
Conclusion Cardiac ion channel genetic testing in autopsy-
negative sudden death victims has a high diagnostic yield,
with identification of the disease in 40 % of families. First-
degree family members should be offered predictive testing,
clinical evaluation, and treatment with the ultimate goal to
prevent sudden death.
Keywords Sudden unexplained death . Sudden cardiac
death .Molecular autopsy . LongQTsyndrome .
Catecholaminergic polymorphic ventricular tachycardia
Abbreviations
BrS Brugada syndrome
CPVT Catecholaminergic polymorphic ventricular
tachycardia
LQTS Long QT syndrome
MLPA Multiplex ligation-dependent probe amplification
SCD Sudden cardiac death
SUD Sudden unexplained death
SQTS Short QT syndrome
Introduction
Sudden cardiac death (SCD) in the young is a tragic event,
with an incidence of 1–2 per 100,000 per year, in the age
group 15 to 35 years old [1–4]. SCD is defined as a witnessed,
natural unexpected death from cardiac causes occurring with-
in 1 h after onset of symptoms in a previously healthy person
or an unwitnessed natural unexpected death of a person ob-
served to be well within 24 h of being found dead [5]. Stan-
dard forensic autopsy is often unsuccessful in determining the
causes of sudden death [1, 6–8]. Negative toxicology and a
structurally and histologically normal heart is found in up to
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53 % of these cases, commonly referred to as autopsy-nega-
tive, sudden unexplained death (SUD) [1, 3, 9]. There are
several conditions difficult to discover at autopsy that may
cause SUD. Inherited cardiac diseases such as channelopa-
thies and cardiomyopathies are a plausible cause of such
autopsy-negative SCD cases and may explain a significant
number of these events [10–13]. Studies have shown that ge-
netic testing may identify a cardiovascular cause of death in up
to 30 % of these cases [11, 14–19]. Long QT syndrome
(LQTS), short QT syndrome (SQTS), Brugada syndrome
(BrS), and catecholaminergic polymorphic ventricular tachy-
cardia (CPVT) causing isolated electric dysfunction are due to
defective genes encoding subunits of cardiac ion channels
(K+, Na+, or Ca2+) or ion channel regulatory proteins [20,
21]. Disturbed ion flow is the substrate to ventricular arrhyth-
mias causing syncope and increased risk of SCD, which char-
acterize these disorders. Syncope is the most common symp-
tom in ion channel disorders, although cardiac arrest may be
the first clinical manifestation in apparently healthy subjects.
In LQTS, death is the first symptom of the disease in 10–15%
of cases, [21] whereas in CPVT, death can be the first clinical
presentation in up to 30% of cases [22]. The mean penetrance
of pathogenic RYR2 variants causing CPVT is 83 %, with
mortality rates of 30–50 % by age 35 years, and consequently,
asymptomatic carriers are rare [20, 22]. It is also useful to test
for cardiomyopathies such as hypertrophic cardiomyopathy
(HCM) and arrhythmogenic right ventricular cardiomyopathy
(ARVC) as structural changes in the cardiac tissue connected
with these diseases can be difficult to discover at autopsy [17].
In this nationwide prospective study, our first aim was to de-
termine the value of molecular genetic autopsy in young SUD
victims by genetic screening of genes important for LQTS,
SQTS, BrS1, and CPVT. Mutation carriers are often unaware
of their disease, and unfortunately, sudden death in many
cases is the first chance to reveal the disorder. Molecular au-
topsy can give an explanation to the sudden death, which is
important for the mourning process of the family [23]. The
findings of an inherited genetic disorder also provide an op-
portunity to offer first-degree family members cascade screen-
ing; identification of mutation carriers can save future lives
[16, 24, 25]. Our second aim was to offer first-degree relatives
genetic testing and medical surveillance to mutation carriers.
Methods
Inclusion criteria
Between January 2009 and December 2011, the Swedish de-
partments of forensic medicine were invited to send whole
blood in EDTA tubes and tissue samples from cases of
SUD. Toxicological analysis including illicit drugs and nar-
cotics was performed in all cases. Histological examination of
the heart were performed, comprising both the left and right
ventricle, and in some cases also the conduction system, the
average number of samples taken from the heart was 11 with a
range from 3 (one case) to 26. The specimens were examined
by trained investigators in haematoxilin-eosin staining as well
as PTAH staining. To be included in the study, the deceased
had to be 1–35 years old and the death had to be sudden,
unexpected, and unexplained after comprehensive medicole-
gal autopsy. Unnatural causes of death such as trauma, mur-
der, suicide, or intoxication were excluded. In total, 15 SUD
victims (10 male and 5 female, medium age at death 15 years)
fulfilled these criteria and were included in the study.
Clinical data
Data on included SUD victims were collected from forensic
autopsy reports and police reports. Information on preceding
symptoms and medical history of the deceased was assembled
from these sources supplemented with interviews with first-
degree relatives and medical records when available.
Genetic analyses
The genetic analyses and interpretation of pathogenicity of
sequence variants have been performed as part of ordinary
health care diagnostics at a clinical genetics laboratory expe-
rienced with sequence analysis of ion channel disorders. DNA
was extracted from blood or tissue samples using standard
salting-out methods. DNA were analyzed for sequence vari-
ants in all protein-coding exons and their flanking splice site
regions of the genes KCNQ1 (NM_000218.2 and
NM_18 1 7 9 8 . 1 ) , KCNH2 (NM_00 0 2 3 8 . 2 a n d
NM_172057.1), SCN5A (NM_198056.1), KCNE1
(NM_000219.2), and KCNE2 (NM_172201.1) using PCR
and bidirectional sequencing on an ABI3500 Genetic Analyz-
er (Applied Biosystems, Foster City, CA, USA). DNA were
also analyzed for sequence variants in the functionally most
important exons (8–15, 44–50, 83, 88–105) of the gene RYR2
(NM_001035.2). Two cases with pathogenic sequence vari-
ants in the KCNQ1 gene were only screened for sequence
variants in the KCNQ1 gene. Primers were M13-tagged and
modified from Jongbloed et al. or designed with Primer3 soft-
ware (primer sequences are available upon request). To detect
deletions or duplications, five samples were analyzed using
multiplex ligation-dependent probe amplification (MLPA)
and the SALSA P114-A2 kit (MRC-Holland). This kit covers
exons 1B, 1–4, 6–13, and 15–16 ofKCNQ1, exons 1B, 1–4, 6,
9–10, and 14 of KCNH2, exons 1–2 of KCNE2, exons 2–4 of
KCNE1, and exons 2, 4, 25, and 27 of SCN5A. Direct DNA
sequencing of the protein coding exon was used for cascade
screening of family members.
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Interpretation of identified sequence variants
Sequences were evaluated using the Sequencer software ver-
sion 4.9 (Gene Codes Corporation, MI, USA) and compared
with a reference genomic sequence. All identified variants
were denoted using accepted nomenclature recommended by
the Human Genome Variation Society. In silico predictions
were made for all identified sequence variants using the
Alamut software version 2.2 (Interactive Biosoftware, Rouen,
France). The Alamut software assists in evaluation of mis-
sense variants by compiling output from a number of bioin-
formatic prediction tools, including PolyPhen, SIFT, Align-
GVGD, andMutationTaster [26–28]. Novel missense variants
were tested for presence in 200 control chromosomes of the
same population and checked for presence in the 6500 control
exomes of the NHLBI Exome sequencing project.
Ethics approval
The Regional Ethical Review Board in Umeå, Sweden, ap-
proved this study. All first-degree relatives have given their
written informed consent.
Results
Fifteen SUD victims aged 1–35 years with a structurally
normal heart at autopsy were referred for post-mortem ion
channel genetic testing, during the period 2009–2011. We
estimate that this represent approximately 50 % of SUD
cases in this period, according to ongoing investigation of
SCD among the young in Sweden 2000–2010 (unpub-
lished data). Toxicological analysis including illicit drugs
and narcotics were negative with exception for two cases
with therapeutic concentrations of relatively harmless
drugs. All cases had normal macroscopic hearts, with the
exception of two obese individuals (BMI 33 and 35) who
had mild enlargement of their hearts. Histological exami-
nation of the left and right ventricle of the heart and in
some cases also the conduction system showed no patho-
logical changes that could explain the deaths. Clinical
characteristics of the SUD cases are summarized in Table 1.
The mean age of death of the SUD victims was 15.5±
13 years (mean±SD), range 2–28 years. Two of the SUD
victims had a family history of sudden death at the time of
death. The majority of the subjects, 9/15 (60 %) died
during rest or sleep. Two subjects (13 %) died during
physical activity: one after hurrying to the bus stop and
one drowned. Two subjects died during daily activity: one
sitting in his classroom at school and one died in a car
accident. Two subjects died at home without anyone
knowing details of the event (Table 1).
Genetic testing of ion channel genes and clinical
description of cases
Genetic screening of the KCNQ1, KCNH2, SCN5A, KCNE1,
KCNE2, and RYR2 genes revealed four LQTS and two CPVT
mutations (40 %). There were no deletions or duplications
detected with MLPA. None of the pathogenic sequence vari-
ants had previously been reported in the literature, dbSNP, or
1000 Genomes, and none were identified in the NHLBI Ex-
ome Sequencing Project database (ESP), where >6000
European-American and African-American individuals were
available. All of the novel variants were predicted to be path-
ogenic according to at least two bioinformatic tools [26–28].
Characteristics of the identified pathogenic sequence variants
are given in Table 2.
Identified LQTS mutations
Individual 1 A pathogenic sequence variant in the KCNQ1
gene (Gly220Lys) was identified in a 28-year-old adopted
female who was found dead at home during daytime. The
woman had given birth to a child 9 months prior to her death.
She was depressed, had disturbed sleeping pattern, and was
treated with benzodiazepines. She had experienced syncope
2 days prior to the death. The physician at the hospital judged
the episode as a vasovagal syncope, and no ECG was taken.
The child did not carry the pathogenic sequence variant, and
no other family members were available for genetic testing.
Individual 2 A pathogenic sequence variant in the KCNQ1
gene (His240Arg) was identified in an 8-year-old girl who had
a cold and died during sleep. Predictive testing of family
members revealed three carriers of the pathogenic sequence
variant. The mother of the deceased child was found to be a
carrier; she was adopted, and nothing is known about her
biological parents/siblings. Two siblings were also carriers
of the pathogenic sequence variant; one of them has a
prolonged QT duration; but none of them have experienced
syncope.
Individual 3 A pathogenic sequence variant in the
KCNQ1 gene (Ala370Val) was identified in an 18-
year-old man who was found dead on the floor at home.
Toxicology examinations showed alimemazine and al-
prazolam in normal therapeutic concentrations in his
blood and 1.06‰ ethanol in femoral blood. Cascade
screening of family members identified four mutation
carriers and three none carriers. Two of the carriers have
experienced symptoms possible due to LQTS: his
grandmother has felt dizziness while swimming a cou-
ple of times, and his uncle has experienced dizziness
and pre-syncope.
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Individual 4 A pathogenic sequence variant in the KCNH2
gene (Ser668Leu) was identified in a 14-year-old boy who
died sitting at his desk in school. Cardiopulmonary resuscita-
tion was started within minutes but was unsuccessful. The boy
was treated with tomoxetine due to attention deficit hyperac-
tivity disorder (ADHD). The boy was adopted; therefore, no
genetic investigation of parents or siblings was possible.
Identified CPVT mutations
Individual 5A pathogenic sequence variant in the RYR2 gene
(Ser4168Thr) was identified in an 18-year-old man, who col-
lapsed having hurried to the bus stop. Resuscitation was un-
successful. The man had been resuscitated 3 years earlier after
a similar event and thoroughly investigated without any path-
ological cardiac findings. He had no current symptoms pro-
ceeding death and no treatment. Four weeks after his death,
prior to the molecular genetic diagnosis, his younger sister
died suddenly when walking back to school after a swimming
lesson. She was later found to be a mutation carrier. The sister
was born with a tetralogy of Fallot; she had recurrent symp-
toms of palpitations and syncope. Genetic testing showed that
their mother and maternal grandfather also carried the muta-
tion, although neither of them had experienced any symptoms.
The maternal great grandfather had experienced syncope and
died suddenly unexpected at the age of 46 years, and a mater-
nal grand uncle died suddenly at the age of 64 years; however,
we do not know their carrier status. Three family members
tested negative for the familial mutation.
Individual 6A pathogenic sequence variant in the RYR2 gene
(Asp401Gly) was identified in a 14-year-old boy who
drowned, despite that he was a good swimmer. The pathogen-
ic sequence variant was found to be de novo since none of the
family members carried the mutation.
In nine of the 15 evaluated cases, we did not identify a
disease causing sequence variant; five of them had experi-
enced pre-mortal symptoms, and one had a family history of
SUD (Table 1).
Discussion
This is to our knowledge the first prospective nationwide mo-
lecular genetic screening study of the LQTS, SQTS, BrS1, and
CVPT genes in SUD victims. Genetic screening of cardiac-
channel genes revealed six pathogenic sequence variants
(40 %) among 15 afflicted SUD victims, four LQTS muta-
tions, and two CPVT mutations; ten first-degree family mem-
bers were found to be carriers and 11 noncarriers. None of the
identified mutations had previously been described; thus, all
of them were unique to this Swedish cohort. In published
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(≈60 %) [29–31]. We have recently described the LQTS mu-
tation panorama in Sweden, and almost one third (28%) of the
identified mutations were novel [32].
Comparison to other studies
Skinner et al. evaluated the LQT genes in the first prospective
population-based series of SUD victims and identified five
pathogenic sequence variants in 33 individuals (15 %) [14].
The diagnostic yield concurs with the result in a Danish study
but is lower than in our present study, and in the retrospective
autopsy studies from the Mayo clinic and from New Zealand
[11, 15, 33]. In a Danish cohort of SUD cases, pathogenic
sequence variants was identified in five of 44 (11 %); cases
were tested for sequence variants in the LQT1–3 genes [15].
Tester et al. showed in a retrospective autopsy study that one
third (17/49) of young SUD cases had verified genetic causes:
LQTS (20%) or CPVT (15%) [11]. Gladding et al. usedDNA
fromGuthrie cards collected for newborn metabolic screening
and identified disease-causing sequence variants in four of 19
SUD cases (21 %) [33]. The high yield in our present study
may be due to sequencing also of the RYR2 gene, ascertain-
ment bias, or a low number of cases. Recently, Bagnall et al.
used exome sequencing of 27 genes and identified nine rare
variants in a subset of 28 SUD cases (32 %) [34]. Next gen-
eration sequencing and whole exome sequencing will likely
be a more effective strategy to uncover the etiology of SUD,
although there are limitations and disadvantages of such ap-
proaches, including the identification of variants of unknown
significance and Bco-incidental^ genetic pathogenic sequence
variants that predispose to adult-onset potentially incurable
conditions.
Pre-mortal symptoms are common
In this study, a man with CPVT had been resuscitated after
cardiac arrest 3 years before death, and a woman with LQTS
experienced syncope 2 days before she died. The other
genotype-positive SUD cases had no reported cardiac-related
pre-mortal symptoms. In nine individuals, we did not identify
pathogenic sequence variants coding for ion channel disor-
ders; five of these had experienced pre-mortal symptoms such
as palpitations or seizures. Medical care was seeked by three
of them, but no ECGswere taken. In a Swedish SCD cohort of
15–35 year olds between 1992 and 1999, as many as 46% had
requested medical advice because of symptoms before suffer-
ing from SCD [35]. It is possible to identify patients with
syncope requiring further evaluation for cardiac etiology
[36]. Tretter et al. evaluated syncope in a pediatric setting:
using the characteristics in the medical history, physical ex-
amination, and ECG, to identify all patients with cardiac eti-
ology [36]. There could be cardiac explanations also to the
SUD cases in our study, such as cardiomyopathies with minor
visible changes, inflammatory injury of the electrical system
in the heart, or pathogenic sequence variants that we were not
able to identify. The SUD cases could also have undetected
noncardiac background such as epilepsy or drug-related
causes.
Activity at time of death
Syncope usually occurs during exercise or acute emotions,
due to torsade de pointes (TdP) in LQTS and due to fast
ventricular tachycardia in CPVT [21, 22]. Most often, there
is a spontaneous recovery of bidirectional or polymorphic
ventricular tachycardia and TdP. However, the arrhythmia
may degenerate into ventricular fibrillation, subsequently
leading to sudden death if no resuscitation is available [21,
22]. In this study, two out of six carriers of a pathogenic
sequence variant died during exercise: one while running
(LQTS) and one while swimming (CPVT). Increased risk
for death while swimming is recognized both in CPVT and
LQTS (especially the LQT1 subtype) [21, 37]. In a post-
mortem series of drowning victims, pathogenic sequence
Table 2 Characteristics of pathogenic sequence variants found in 15 victims of sudden unexplained death aged 1–35 years in Sweden 2009–2011
Gene Exon Nucleotide change Amino acid change Region Domain Polyphen-2a SIFT MutationTasterb Align-
GVGDc
KCNQ1 4 c.658C>A p. Gly220Lys S3-S4 Ion transport Possibly damaging Tolerated Disease causing C0
5 c.719A>G p. His240Arg S4 Ion transport Benign Deleterious Disease causing C25
8 c.1109C>T p. Ala370Val C-term – Probably damaging Deleterious Disease causing C65
KCNH2 8 c.2003C>T p. Ser668Leu S6 Probably damaging Deleterious Disease causing C65
RYR2 14 c.1202A>G p. Asp401Gly N-term MIR motif Possibly damaging Deleterious Disease causing C65
90 c.12502T>A p. Ser4168Thr Cytosol – Possibly damaging Deleterious Disease causing C55
SIFT sorting intolerant from tolerant
a Polyphen-2, polymorphism phenotyping v2, predicts possible impact of an amino acid substitution on the structure and function of the protein
bMutationTaster calculates probability for the alteration to be either disease causing or a harmless polymorphism
cAlign-GVGD Align Grantham variation and Grantham distance, ordered from most likely (C65) to interfere with function to least likely (C0)
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variants in the RYR2 gene were identified in 20 % [37, 38].
The majority in our study died during normal daily activity or
sleep, which is in accordance with other studies [25].
Certain drugs prolong the QT duration
It is well known that certain drugs prolong the QT duration
and might induce TdP in individuals with LQTS [39]. In this
study, three of four SUD cases with an identified pathogenic
LQT variant were on medication, thus revealing therapeutic
levels of medicine in the blood toxicology screening. Both the
drugs alimemazine and tomoxetine are known to prolong the
QT duration, although the risk for serious cardiovascular ad-
verse events, including significant increases in QTc and sud-
den cardiac death, is judged to be low. However, great caution
is advised when considering stimulant and nonstimulant med-
ications for patients of any age with a diagnosis of ADHD and
a personal or family history or other known risk factors for
cardiovascular disease [40]. We do not know if the treatment
was of significance for the death of the SUD victims in this
study, but we know that the medication was given without
knowing the vulnerability due to an at that time undiscovered
disease.
Autopsy for crime investigation
Post-mortem DNA analysis of SUD victims opens new diag-
nostic possibilities but is to our knowledge not yet included in
routine investigation in any country. This is probably because
these cases often are handled in the juridical/legal system; it is
in some countries not legal to do these examinations without
permission of the next kin. The main purpose of the forensic
autopsy is to investigate possible crimes and only secondary
to investigate cause of death due to disease. Furthermore, the
analyses have so far been very expensive, especially in the
perspective that the investigations are not carried out as part
of a medical mission. It is recommended that all SUD victims
undergo expert cardiac pathology to rule out a structural heart
disease [41]. Collection of blood in an EDTA tube or a blood
spot card or a frozen sample of tissue is recommended in cases
of SUD and sudden unexpected death in infancy for subse-
quent DNA analysis/genetic testing [41].
Clinical implication
If post-mortem genetic testing was to be performed routinely,
these autopsy-negative cases could get a diagnosis, first-
degree relatives could have an explanation to the death, and
familymembers could be offered predictive testing. Treatment
and surveillance of genotype-positive individuals can reduce
morbidity and mortality, and noncarriers would benefit from
certain knowledge of not being at risk.
Limits of the study
Not all genes or exons involved in cardiac ion channel disor-
der were analyzed. Only about 50 % of the SUD victims were
referred for genetic testing. The relatively low participation
rate may be due to not considering the molecular diagnosis
option immediately at autopsy, but first after all other diagnos-
tic options have failed.
Conclusions
Our study shows that cardiac-channel focused investigation is
of great value in establishing the cause of death in unexplained
sudden death, thus supporting the transition of a molecular
genetic autopsy into routine clinical practice. In view of what
is stated above concerning the primary objective of the inves-
tigation of these deaths, it is necessary to establish a partner-
ship between health care and justice; both to implement ade-
quate sampling but also to finance analyses. Furthermore, is-
sues relating to handling of positive test results and privacy
problems have to be solved.
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